STOCKS TELEGRAPH

Tag: ATOS

  • Why Atossa Therapeutics, Inc. (Nasdaq: ATOS) stock tumbled in the pre-market trading?

    Why Atossa Therapeutics, Inc. (Nasdaq: ATOS) stock tumbled in the pre-market trading?

    Atossa Therapeutics, Inc. (Nasdaq: ATOS) stock dropped down -38.46 to $0.88 in the Early hour’s session today after a clinical-stage biopharmaceutical corporation looking to find and grow novel drugs in areas of substantial unmet medical need with a current emphasis on breast cancer and COVID-19, revealed the offering of an underwritten public offering with estimated cumulative gross proceeds of $20.0 million before deducting underwriting discounts, commissions.

    The shares issued by the Corporation comprise of I 14,575,000 shares, each consisting of one share of common stock and 0,75 Warrants for the acquisition of one share of common stock for $1.00 each unit and (ii) 5,425 units, each consisting of one share of Series C Convertible Preferred Stock with a fixed valuation of $1,000 each share and convexed. The Warrants will have an exercise price of $1.00 per share, will be automatically enforceable, and will expire four years from the date of issue.

    Shares of Common Stock, Preferred Stock, and associated Warrants can only be acquired together in the bid but will be distributed separately and will be instantly separable upon issuance. According to the standard closing terms, the offer is scheduled to close on or around 11 December 2020.

    Following the deal, Maxim Group LLC serves as the sole book manager.

    Atossa Therapeutics has given Maxim Group LLC a 45-day option to buy up to an extra 3,000,000 shares of Common Stock and Warrants to purchase up to an additional 2,250,000 shares of Common Stock a public offering price of fewer discounts and commissions.

  • Atossa Therapeutics, Inc. (ATOS) provides promising findings from the Phase 1 Clinical Trial of AT-301 Nasal Spray for COVID-19

    Atossa Therapeutics, Inc. (ATOS) provides promising findings from the Phase 1 Clinical Trial of AT-301 Nasal Spray for COVID-19

    Atossa Therapeutics, Inc. (Nasdaq: ATOS) a biotech giant with a focus on breast cancer and COVID-19, today announced blinded results from its Phase 1 clinical trial using Atossa ‘s patented AT-301, delivered through a nasal spray.

    In this study, AT-301 was found to be safe and well-received at two different dose levels over 14 days, in both single and multiple-dose formulations. For patients experiencing symptoms with COVID-19, AT-301 is being created to be used at home. In order to treat COVID-19 at home, there are currently no FDA-approved therapies.

    Atossa helps to determine potential collaborators who are designing diagnostic tests for COVID-19 so that AT-301 nasal spray can be co-developed and promoted with the purpose of making accessible AT-301 therapy when a person shows symptoms and test positive for the coronavirus.

    Atossa plans to further improve its nasal spray to prevent infection with COVID-19, specifically for all of those living in high-risk environments such as COVID-19 infected patients, health care workers, and emergency respondents and teachers.

    Although some manufacturers are still developing a vaccine for SARS-CoV-2, Atossa considers that therapies such as AT-301 provide a major market opportunity. The production and availability of conventional vaccines can also take years. Surveys have found that when a conventional vaccine is initially available, many people would not receive a vaccine 100%, particularly if multiple types of Coronavirus appear.

    The stock of the Healthcare sector started trading yesterday at $1.33. During the session, it climbed to $1.49 and dropped to $1.25 before closing at the price of $1.36. The stock with a market capitalization of $14.47M had a volume of 280.54 k.